major breakthrough is on the horizon for Crohn's disease

December 1997

A major breakthrough is on the horizon for Crohn's disease.

A new biotech drug is expected next year...called Avakine (infliximab) by Centocor.

Avakine is a monoclonal antibody that blocks tumor necrosis factor...and therefore, slows inflammation.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote